Understanding the Guidance: What, Why, How
In September 2025, the U.S. Food and Drug Administration (FDA) issued a nonbinding guidance for industry titled “Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.” U.S. Food and Drug Administration
This document gives detailed recommendations for sponsors developing therapeutic protein biosimilars, especially how to design and perform the comparative analytical studies needed to show that a proposed therapeutic protein product is biosimilar to a licensed reference product under section 351(k) of the PHS Act. U.S. Food and Drug Administration
It focuses on the chemistry, manufacturing, and controls (CMC) aspect of biosimilar applications: how to characterize similarity (physicochemical, functional, impurities, etc.), how many lots to test, what assays, how to deal with non-U.S. comparator products, how to do data analysis and risk assessment, etc. U.S. Food and Drug Administration
Key Elements of the Guidance
Here are the major sections and their important points, with deeper detail:
| Section | What’s Covered | Important Takeaways |
|---|---|---|
| Introduction & Background | Why this guidance matters; regulatory path (351(k) pathway) for biosimilars; what “biosimilar” means, distinction from “interchangeable.” U.S. Food and Drug Administration+1 | Background shows that analytical ability has improved; the regulatory standard demands high similarity, notwithstanding minor differences in inactive components. Also, sponsors must build their development programs with analytical data early. U.S. Food and Drug Administration |
| Scope | Applies specifically to recombinant therapeutic protein products, including monoclonal antibodies for prophylactic use. Guidance is about biosimilarity (not interchangeability) though some overlap, especially in analytics. U.S. Food and Drug Administration | Recognizing that some principles may also inform other protein products (e.g. naturally-derived), but explicit scope is recombinant therapeutic proteins. Early consultation with FDA is encouraged. U.S. Food and Drug Administration |
| General Principles | Advances in analytic techniques; importance of understanding limitations; need to characterize structural attributes (primary, higher order), functional activity, etc. U.S. Food and Drug Administration+1 | The guidance makes clear that deep, robust analytics are the foundation. Functional and physicochemical data feed into decisions on how much clinical testing might still be required or whether a selective/targeted approach might be acceptable. U.S. Food and Drug Administration |
| Factors for Comparative Analytical Assessment | Expression system, manufacturing process, physicochemical properties (e.g. higher order structure, post-translational modifications), functional assays, impurities, reference materials, finished product, stability. U.S. Food and Drug Administration | Each factor can introduce variation. E.g., different cell line or expression host can lead to different glycosylation, impurities; formulation and excipients can affect stability. Sponsors need to justify differences and assess their impact. U.S. Food and Drug Administration |
| Comparative Analytical Assessment | Number of lots (reference product, proposed product), use of non-U.S. comparators and how to bridge to U.S. licensed reference, risk assessment of quality attributes, quantitative vs qualitative analyses, acceptance criteria, data analysis plans. U.S. Food and Drug Administration | The guidance recommends at least ~10 lots of reference product over time (spanning expiry dates) to capture lot‐to-lot variability; for proposed product 6-10 lots including clinical, validation, commercial batches. Acceptance criteria should be scientifically justified, using statistical / graphical / quality range methods. Quantitative data for high/moderate risk attributes; qualitative for low risk or those not measurable. U.S. Food and Drug Administration |
| Conclusions | How to interpret differences, when minor differences may be acceptable, and when they might require additional data; importance of “totality of evidence.” U.S. Food and Drug Administration | Even if some assay(s) show differences, the overall weight of evidence across physicochemical, functional, and other quality attributes is what matters. Justification is key. Early dialogue with FDA encouraged. U.S. Food and Drug Administration |
Implications: What This Means in Practice
Here are what the guidance suggests in real-world biosimilar development, and what organizations need to watch out for.
- Early Analytical Insights are Critical
‒ Sponsors need to start comparative analytics early, even before full clinical trials, so that lots of reference product are characterized, and functional/structural insights guide downstream design. - Lot Selection Matters
‒ To capture variability in the reference product, multiple lots over time/expiry are needed. For proposed product, lots should represent different scales, process changes, and ideally lots used in clinical and commercial-scale manufacture. - Expression System / Manufacturing Differences Must Be Justified
‒ If your biosimilar is produced in a different cell line or expression host than the reference, you’ll face questions about what differences that introduces (glycosylation, impurities, etc.). You’ll need data to show these don’t lead to clinically relevant differences. - Assay Design, Sensitivity & Orthogonality
‒ Use multiple, complementary (orthogonal) methods to detect differences. Some assays are more sensitive; some may detect functional differences more clearly. Understand assay limitations. - Risk Assessment & Attribute Ranking
‒ Not all quality attributes are equal. Those most likely to affect safety, potency, immunogenicity, PK/PD must be identified, risk ranked, and handled with more scrutiny. - Non-U.S. Comparator Products
‒ Using non-U.S. licensed comparator (from e.g. Europe, elsewhere) is possible, but bridging data to U.S.-licensed reference product is essential. All pairwise comparisons are needed: proposed vs U.S reference; proposed vs non-U.S comparator; non-U.S comparator vs U.S reference. - Data Presentation and Acceptance Criteria
‒ Sponsors must propose acceptance criteria, quality ranges, analysis plans; explain how much variation is acceptable, why; use statistical justification. Where quantitative is not possible, qualitative or graphical comparisons are needed.
Potential Challenges & Critical Considerations
While the guidance gives clarity, implementing it comes with challenges:
- Access to multiple lots of the reference product: For some biologics, reference product lots may be limited, or hard to source, or expensive.
- Analytical method limitations: Not all labs have state-of-the-art equipment or capability. Some higher order structure analyses, posttranslational modifications may be difficult to resolve.
- Defining acceptance criteria: Especially for novel or complex proteins, determining what deviation is clinically meaningful vs not is non-trivial.
- Bridging non-U.S. comparator lots: May require substantial data, and differences in formulations/excipients may complicate comparisons.
- Regulatory risk: Even if analytics look good, residual uncertainties (from unknown structure-function relationships) might require more clinical or immunogenicity data.
- Cost & time: Extensive lot testing, stability studies, functional assays, etc. are resource-intensive.
Why This Guidance is Important
- It reflects state of the science: analytical methods have improved over decades. The FDA is using these capabilities to reduce reliance, where possible, on bigger and more costly clinical studies by leaning more on strong analytical data.
- Helps standardize expectations: for companies developing biosimilars, knowing what FDA expects in terms of number of lots, test methods, risk ranking helps reduce surprises.
- Enables more efficient development: if differences are well characterized and justified, certain clinical or functional studies might be streamlined, reducing time to market.
- Patient benefit: more biosimilars entering the market means more competition, potentially lower costs, improved access.
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.